Retevmo Capsule
NDC Package 0002-2980-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Retevmo (selpercatinib) capsules is none. This formulation utilizes a capsule delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-2980 and is authorized under FDA application NDA213246.

Identification & Billing

NDC Package Code
0002-2980-60
Package Description
60 CAPSULE in 1 BOTTLE
Product Code
0002-2980
11-Digit Billing Format
00002298060
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
60 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Retevmo
Non-Proprietary Name
Selpercatinib
Substance Name
Selpercatinib
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SELPERCATINIB 80 mg/1
Pharmacologic Class
Usage Information
None.

Regulatory & Marketing

Labeler Name
Eli Lilly And Company
Product Type
Human Prescription Drug
FDA Application #
NDA213246
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-08-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0002-2980). Click a package code to view its specific billing and regulatory data.

0002-2980-26
120 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0002-2980-60 identifies a specific commercial package of 60 capsule in 1 bottle of Retevmo, a human prescription drug labeled by Eli Lilly And Company. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This capsule is formulated for oral use and contains selpercatinib as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on May 08, 2020. The current certification is valid through December 31, 2026.

How is this Eli Lilly And Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002298060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0002-2980-60
11-Digit CMS (5-4-2)
00002-2980-60

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.